These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15163266)

  • 21. Valproic acid and risperidone.
    van Wattum PJ
    J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):866-7. PubMed ID: 11501681
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-a-day controlled-release dosage form of divalproex sodium I: formulation design and in vitro/in vivo investigations.
    Qiu Y; Cheskin HS; Engh KR; Poska RP
    J Pharm Sci; 2003 Jun; 92(6):1166-73. PubMed ID: 12761806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
    Stahl SM; Grady MM
    Curr Med Chem; 2004 Feb; 11(3):313-27. PubMed ID: 14965234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Zhang Y; Lee LL; O'Dea R
    Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
    Dutta S; Reed RC; Cavanaugh JH
    Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC; Dutta S
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy.
    Lunde JL; Nelson RE; Storandt HF
    Pharmacotherapy; 2007 Aug; 27(8):1202-5. PubMed ID: 17655519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine.
    Pantelis C; Adesanya A
    Aust N Z J Psychiatry; 2001 Aug; 35(4):544-5. PubMed ID: 11531743
    [No Abstract]   [Full Text] [Related]  

  • 30. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
    Reed RC; Dutta S; Liu W
    Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
    Dutta S; Reed RC
    Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
    Dutta S; Reed RC
    Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Branded versus generic clozapine: bioavailability comparison and interchangeability issues.
    Lam YW; Ereshefsky L; Toney GB; Gonzales C
    J Clin Psychiatry; 2001; 62 Suppl 5():18-22; discussion 23-4. PubMed ID: 11305844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absorption of valproic acid suppositories in human volunteers.
    Holmes GB; Rosenfeld WE; Graves NM; Remmel RP; Carlson GH; Kriel RD
    Arch Neurol; 1989 Aug; 46(8):906-9. PubMed ID: 2502974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monozygotic twins concordant for response to clozapine.
    Vojvoda D; Grimmell K; Sernyak M; Mazure CM
    Lancet; 1996 Jan; 347(8993):61. PubMed ID: 8531572
    [No Abstract]   [Full Text] [Related]  

  • 36. Extended-release divalproex sodium for patients with side effects from delayed-release divalproex sodium.
    Longo LP
    Am J Psychiatry; 2005 Aug; 162(8):1548-9. PubMed ID: 16055790
    [No Abstract]   [Full Text] [Related]  

  • 37. Very high cytochrome P4501A2 activity and nonresponse to clozapine.
    Bender S; Eap CB
    Arch Gen Psychiatry; 1998 Nov; 55(11):1048-50. PubMed ID: 9819075
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
    Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
    J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete ultrarapid metabolism of flupentixol in 42 year old patient suffering from chronic schizophrenia.
    Koch HJ; Zellmer H
    Therapie; 2013; 68(2):117-8. PubMed ID: 23773353
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.